Safety, Tolerability and PK of PXL770 in Healthy Male Subjects

Summary

PXL770 is a direct activator of 5' adenosine monophosphate-activated protein kinase (AMPK) being developed by Poxel S.A. for the treatment of type 2 diabetes mellitus (T2DM). In Part A of this study, we'll test the safety, tolerability and pharmacokinetics (PK) of repeated doses. In Part B, we'll co-administer PXL770 and rosuvastatin (a HMG-CoA reductase inhibitor) to assess any drug-drug interaction.

Timeline

Start

2017-08-21

Primary completion

2018-03-16

Completion

2018-03-16

Drugs

Indications